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Extended vs Small field irradiation in High Risk Post Esophagectomy Patients Receiving Combined Chemoradiation Therapy : A
Decade Experience In Treatment Of Esophageal Cancer.
AUTHORS: Edward Yu 1 , Patricia Tai 2 , George Rodrigues 1, Robert Ash 1 , Larry Stitt 1 , Rashid A. Dar 1, Pauline Truong
3 , Gregory M Videtic 4 , Richard Malthaner 1 , Richard Inculet 1 , Anna Tomiak5 , Jawaid Younus 1 , Brian Dingle 1 , Walter
Kocha 1, Mark Vincent1 .
OBJECTIVE: To assess the impact of extended field irradiation with anastomotic coverage on local recurrence in high risk
resected esophageal cancer patients.
METHODS: From 1989-1999, high risk resected esophageal cancer cases receiving post-resection chemoradiation were
reviewed. Adjuvant chemotherapy consisted of four cycles of fluorouracil - based regimens. Loco-regional irradiation with or
without coverage of anastomotic site had radiation a dose range from 45-60 Gy at 1.8-2.0 Gy / fraction given with initial anterior-
posterior / posterior-anterior arrangement with either extended (with anastomotic coverage), or small (without anastomotic
coverage) field followed by oblique fields for boost.
RESULTS: One hundred eighty-eight charts were reviewed. Seventy-two patients were eligible for post-resection
chemoradiation. Three patients had disease progression prior to therapy, and 69 patients were analyzed. The median age was 60
years (range 35-82years) with 94 % T2-3 N1 and 65% were adenocarcinoma. As of January 2005 median follow up was 30.5
months ( range 3-142 months), the two - and five- year overall survival rates were 50% and 31%, respectively . First relapse rate
after adjuvant therapy was 71% ( n=49) and median time to relapse was about 30 months. Loco-regional relapse with small field
was 25/35 (71.4%) and 2/14 (14.2%) with extended field (P < 0.001). Recurrence locally to anastomosis or adjacent site was
10/35 (28.6% ) with small field and 0/14 (0%) with extended field (P=0.04).
CONCLUSION: At a minimum of 5-year follow up, there is significant decrease in loco-regional relapse with the use of
extended field in high risk resected esophageal cancer patients. This important improvement trend deserves further exploration in
prospective randomized clinical trials.
Introduction
• Post-operative radiation therapy (RT)1 and post-operative chemoradiation2 have 
been used for esophageal cancer patients deemed high risk for recurrence after 
esophagectomy.  Defining optimal RT target voulme after esophagectomy is 
difficult due to significant changes in patient anatomy and function.
• Some radiation oncologists advocated the inclusion of the anastomotic site 
within the irradiation volume due to concerns for potential increased relapse 
risk, while others did not subscribe to this practice due to concerns for increased 
treatment-related toxicity.  We performed a review of patient outcomes in a 
single institution to investigate the impact of anastomotic coverage in high risk 
esophageal patients who underwent esophagectomy.
1 Fok et al, Surgery:  113, 1993
2 Bedard et al, Cancer:  91, 2001 
Methods and Materials
• Data were analyzed for patients treated at London Regional Cancer Center  
(LRCC) from 1989 to 1999 with a diagnosis for “high risk” resected esophageal 
cancer. “High risk” pathologic findings were defined as T3 or T4 disease  and/or 
regional nodal involvement.
• Adjuvant therapy consisted of chemotherapy followed by concurrent 
chemoradiation. Chemotherapy consisted of 4 cycles of either ECF (epirubicin 
50mg/m2 day 1 and q21 days, 5 fluorouracil 200mg/m2 continuous infusion for 
21 days, and cisplatinum 60mg/m2 day 1 and q21 days), with epirubicin omitted 
during the concurrent phase with RT, or 4 cycles of CF  (cisplatinum 100mg/m2  
day 1 and q21 days), and 5 fluorouracil 1000mg/m2 days 1-4 continuous 
infusion and q21 days).  Total RT dose ranging from 45-60 Gy at 1.8-2.0 Gy 
fraction.  In general 45-50 Gy  was used for microscopic disease while higher 
doses up to 60 Gy were  reserved for patients with margin involvement or 
residual disease. 
• The first phase of RT involved APPA beam arrangement to 30-45 Gy, with 
either extended field  (including anastomotic site with field size range 22x12-
28x12cm, median 24x12cm) or small field  (excluding anastomotic site with 
field size range 12x10-22x12 cm, median 19x12cm) followed by second phase 
cord-sparing, oblique fields for boost with an additional 15-30 Gy.
• The initial target volume defined by margins of 5 cm above and below the pre-
surgical gross tumor volume, as well as a 2 cm margin to cover the mediastinal 
lymph nodes medially and laterally. For “extended field”  the superior margin 
extended 2 cm above the anastomotic site  (Figure 1).
• Boost fields were CT- planned with 2 cm margins around the target volume.  
All patients were treated with high energy mega voltage photon (>6 MV) in 
supine position. Close margin was defined as microscopic tumor cells presented 
within 2 mm of the resection margin.  
• Local relapse was defined as recurrence at or immediatley adjacent to the 
anastomotic site.  Regional relapse was recurrent at the  mediastinum and/or 
peri-esophageal region excluding local relapse.
• Distant relapse was tumor recurrence at the distant site, i.e. brain, liver, and 
lung etc.  Acute treatment toxicities included chemotherapy/RT interruption, 
and late gastrointestinal RT morbidity (RTOG grading system) Grade 2 toxicity 
were also analyzed.  Grade 2 was described as moderate diarrhea and colic with 
bowel movement > 5 times daily, or intermittent bleeding. The marker for any 
toxicity-related treatment break was measured by  the length (in days) of the 
interruption in the chemotherapy or RT schedule arising during the concurrent 
phase of the treatment.   
• Hematological criteria for interruptions during concurrent chemotherapy RT including 
absolute neutrophil count  < 1,000 mm-3 , sepsis or neutropenic fever,  thrombocytes     
<80,000 mm-3 .
• Loco-regional symptomatology including severe esophagitis (i.e. severe 
odynophagia/dysphagia, intolerable pain), impaired nutrition with nausea/vomiting; and 
dehydration require hospitalization.
Results
• 188 esophageal cancer patients eligible for review were identified. 72 had thoracic 
esophageal and GE junction cancer with high risk features post-surgery.  Three patients 
had disease progression prior to treatment, leaving 69 patients for  analysis. The median 
age of the patients  was 60 years ( range 35-82years).  Table 1 shows the patient 
characteristics of the study group.
• As of Jan 2005, follow-up ranged from 3-142 months  with median 30.5 months. The 2-
yr and 5-yr  overall and disease specific survivals were 50 and 31%, 62 and 37.4% 
respectively (Figure 2).   
• For small field  RT the median, 2 yr and 5-yr overall survivals were 32.5 months, 60.5 
and 29.2% respectively; 27.6 months, 42.5 and 34.6% respectively for the extended field  
RT (P= 0.950). 
• The median, 2-yr and 5-yr disease specific survivals, were 36.4 months, 66.1 and 31.9%, 
respectively, for small field  RT; 35.2 months , 59.7 and 49.7% respectively, for the 
extended field  RT  (P= 0.50) (Figure 3).    The first relapse rate after adjuvant therapy 
was 71% (n=49) and the median time to relapse was about 30 months.  Loco-regional 
relapse with small field was 25/35 (71%) and 2/14 (14.2%) with extended field 
(P<0.001) ( Table 2 ).
• The difference between small and extended field  remained statistically significant 
(P=0.003) when adjustment was made  for the effect of margin status.  Recurrence 
locally to anastomosis or adjacent site was 10/35 (28.6%) with small field and 0/14 (0%) 
with extended field (P= 0.04) (Table 3 ).  Complications of extended field  RT were 
reviewed including RT treatment interruption (P=0.71), chemotherapy delays (P=0.26), 
and late gastrointestinal Grade 2 toxicity (P=0.26) were not statistically significant when 
compared with patients treated with small field  RT.   
Conclusion
• Esophageal cancer patients with high risk features of regional nodal involvement, 
positive or close resection margins and T3 or T4 disease, post-operative RT with 
extended field  to include the anastomotic site, improved local-regional disease control 
without added late toxicity upon retrospective analysis.
• Confirmation of these findings and evaluation of acute and chronic toxicity and patient 
quality of life associated with this treatment regimen, require prospective investigation.
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Figure 1a:   Small Field RT
Figure 1b:  Extended Field  RT
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Table 1: PATIENT CHARACTERISTICS
Patient Characteristics All (n=69) SM (n=43) EX (n=26) aP-value
Age
Sex
Pathological
Stage
Type of 
Surgery
Tumor
Pathology
Margin
Status
< 65
> 65
Male
Female
T2,3 N1
T3,4 No
Transhiatal
Transthoracic
Squamous
Adenocarcinoma
Positive/Close
Negative
41(59%)
28(41%)
62(90%)
7(10%)
65(94%)
4(6%)
59(86%)
10(14%)
24(35%)
45(65%)
34(49%)
35(51%)
25
18
38
5
41
2
35
7
15
27
14
29
16
10
24
2
24
2
24
3
8
18
20
6
P=0.781
P=0.598
P=0.601
P=0.523
P=0.676
P<0.01
SM - Small field RT
EX - Extended  field  RT
aChi-Square
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TREATMENT VOLUME LOCAL REGIONAL DISTANT TOTAL (%) 
Small  field 
Extended  field  
25(71.4%) 
2(14.3%) 
10(28.6%) 
12(85.7%) 
35(100%) 
14(100%) 
(a P<0.001 )  ,  a Chi- Square 
( b P<0.001)  ,  b Fisher’s Exact ( two- tails) 
Treatment Volume Relapse Pattern TOTAL  (%) 
ANA NANA  
Small  field 
Extended  field  
10 (29%) 
0 (0%) 
25 (71%) 
14 (100%) 
 
35 (100%) 
14 (100%) 
( b P =0.04) ,   b  Fisher’s Exact( two-tails) 
ANA - Anastomotic 
 NANA- Non-Anastomotic 
Table 3:  TREATMENT VOLUME RELAPSE
Table 2:  TREATMENT VOLUME
